Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalySurgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis.Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.Expert consensus document: A consensus on the medical treatment of acromegaly.Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery.Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional.Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment.Patient-focussed outcomes in acromegaly.Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues.Pharmacokinetic evaluation of lanreotide.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsManagement options for persistent postoperative acromegaly.The place of medical treatment of acromegaly: current status and perspectives.Emerging drugs for acromegaly.Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Adverse events associated with somatostatin analogs in acromegaly.Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study.The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.
P2860
Q26777682-779C517B-B9A2-4916-A1BD-92391998D7D1Q30353080-49CE631A-FCEB-4EE3-8474-389C72489AFDQ30585813-FBC86EF4-8F8B-4436-B315-866D98E8FF0EQ34406566-C3315F30-BAAD-4F41-8CAC-40105C5F7BD0Q35981653-2ADC1224-96E7-42E6-9714-7C6F769C5081Q36270815-FFF5D8D7-744A-4117-9029-CE714DF21148Q36358185-E1D720CF-BCCA-4AD5-A57F-4B586EB60929Q36489627-5CDB148A-95E2-4494-89D3-9C2E05B3841AQ36563998-6CDEC961-C308-4034-8731-AE197FCD3B23Q37530996-81A21FD5-BA86-4233-8B12-9591B244E0E2Q37641076-8C3DE440-A208-4320-8B6F-9B7D5DE9B0A4Q37780553-DCB8DB01-5C8F-43B2-9FC4-BEFFDA2E8FB3Q37980741-C24721A7-9CCD-483B-A216-48A274C3102AQ38049832-E37BCF01-E6C6-4944-A48A-067000507B50Q38100275-1D4BC9B9-608B-433E-A04D-7C3ED88DADBDQ38176659-54E75162-FA82-4D4E-9D69-0BE5C8115276Q38233686-71BE3A08-4215-4484-B6C8-DE3A660AE6D2Q38246440-9F3C0423-0B94-4F50-BBDA-D7E0ABC1EB20Q38259409-1B5B6218-5E6F-43D8-B468-81B4339ED869Q38373377-D77BFF48-C3FA-429F-854B-8DD43EECF357Q38548973-D53A6B9A-65B3-4D5E-AC55-7991D9CDA186Q42023464-E07CC45A-26AB-4998-98B6-40A52BF89A09Q42414991-7CA92FF1-6FBB-47C1-843A-21CBC6398B3B
P2860
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effectiveness of self- or part ...... aïve patients with acromegaly.
@ast
Effectiveness of self- or part ...... aïve patients with acromegaly.
@en
type
label
Effectiveness of self- or part ...... aïve patients with acromegaly.
@ast
Effectiveness of self- or part ...... aïve patients with acromegaly.
@en
prefLabel
Effectiveness of self- or part ...... aïve patients with acromegaly.
@ast
Effectiveness of self- or part ...... aïve patients with acromegaly.
@en
P2093
P2860
P1433
P1476
Effectiveness of self- or part ...... aïve patients with acromegaly.
@en
P2093
David M Cook
Lisa B Nachtigall
Mark E Molitch
Roberto Salvatori
SALSA Study Group
Sandra Blethen
Stephen Chang
Vivien Bonert
P2860
P2888
P304
P356
10.1007/S11102-009-0207-X
P577
2010-06-01T00:00:00Z